![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Under the agreement, Reprocell will provide support for Lantern Pharma's Phase 2 trial of LP-300 (tavocept) in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with TKIs.
Lead Product(s): Dimesna,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: LP-300
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Reprocell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2023
Details:
LP-300, or tavocept (Disodium 2,2’-dithio-bis-ethane sulfonate), is a small molecule entity with cysteine modifying activity on select proteins, works to modulate multiple cellular pathways simultaneously and is potential first-in-class combination agent indicated in NSCLC.
Lead Product(s): Dimesna,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tavocept
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022